Jazz Pharmaceuticals plc – (JAZZ) Earns Outperform Rating from Leerink Swann

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ)‘s stock had its “outperform” rating reaffirmed by Leerink Swann in a research note issued on Monday.

A number of other equities analysts have also recently issued reports on JAZZ. Cowen and Company restated a “positive” rating and set a $190.00 price target on shares of Jazz Pharmaceuticals plc – in a report on Monday. Cantor Fitzgerald restated an “overweight” rating and set a $187.00 price target on shares of Jazz Pharmaceuticals plc – in a report on Tuesday, January 24th. Mizuho increased their price target on Jazz Pharmaceuticals plc – from $127.00 to $152.00 and gave the stock a “buy” rating in a report on Tuesday, February 21st. Stifel Nicolaus cut their price target on Jazz Pharmaceuticals plc – from $200.00 to $190.00 and set a “buy” rating on the stock in a report on Wednesday, March 1st. Finally, BMO Capital Markets restated a “positive” rating and set a $192.00 price target on shares of Jazz Pharmaceuticals plc – in a report on Monday. One analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $177.70.

Analyst Recommendations for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)

Shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded up 6.92% during trading on Monday, reaching $144.09. 1,490,704 shares of the company were exchanged. The company has a market capitalization of $8.61 billion, a PE ratio of 22.48 and a beta of 1.22. Jazz Pharmaceuticals plc – has a one year low of $95.80 and a one year high of $160.00. The firm’s 50 day moving average price is $131.85 and its 200 day moving average price is $119.55.

Your IP Address:

In related news, COO Russell J. Cox sold 4,000 shares of the stock in a transaction on Wednesday, January 18th. The stock was sold at an average price of $128.75, for a total value of $515,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Paul Treacy sold 884 shares of the stock in a transaction on Monday, March 6th. The stock was sold at an average price of $131.97, for a total value of $116,661.48. Following the completion of the transaction, the senior vice president now owns 18,108 shares in the company, valued at $2,389,712.76. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,484 shares of company stock worth $709,335. 3.90% of the stock is owned by company insiders.

Several institutional investors have recently modified their holdings of the company. Tourbillon Capital Partners L.P. raised its stake in Jazz Pharmaceuticals plc – by 1,152.9% in the fourth quarter. Tourbillon Capital Partners L.P. now owns 826,882 shares of the specialty pharmaceutical company’s stock worth $90,155,000 after buying an additional 760,882 shares during the last quarter. Renaissance Technologies LLC raised its stake in Jazz Pharmaceuticals plc – by 70.6% in the fourth quarter. Renaissance Technologies LLC now owns 1,560,300 shares of the specialty pharmaceutical company’s stock worth $170,120,000 after buying an additional 645,500 shares during the last quarter. Norges Bank bought a new stake in Jazz Pharmaceuticals plc – during the fourth quarter worth approximately $61,558,000. Cadian Capital Management LP raised its stake in Jazz Pharmaceuticals plc – by 71.6% in the third quarter. Cadian Capital Management LP now owns 1,311,292 shares of the specialty pharmaceutical company’s stock worth $159,296,000 after buying an additional 547,056 shares during the last quarter. Finally, Victory Capital Management Inc. raised its stake in Jazz Pharmaceuticals plc – by 35,390.5% in the third quarter. Victory Capital Management Inc. now owns 303,444 shares of the specialty pharmaceutical company’s stock worth $36,863,000 after buying an additional 302,589 shares during the last quarter. Institutional investors own 88.56% of the company’s stock.

About Jazz Pharmaceuticals plc –

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/jazz-pharmaceuticals-plc-jazz-earns-outperform-rating-from-leerink-swann/1709279.html

Receive News & Ratings for Jazz Pharmaceuticals plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals plc - and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *